Abstract: The present disclosure provides methods of treatment and/or prophylaxis of viral infections and/or diseases, disorders, and conditions associated therewith such as COVID-19. The disclosed treatment involves administering aminoquinoline drugs, corticosteroids, and antibiotics to subjects in need thereof, and particularly providing such treatments prior to substantial bacterial infection in the lung.

Abstract: The present disclosure provides pharmaceutical compositions comprising interferons (IFNs), methods of treating or preventing viral respiratory infections in subjects thereof using IFNs thereby reducing viral respiratory infections, symptoms thereof, inflammation, and minimizing virus propagation. In some embodiments, the pharmaceutical compositions may comprise at least one IFN, an aminoquinoline, a corticosteroid, and one or more pharmaceutically acceptable excipients, carriers, or diluents; and optionally at least one therapeutic agent, and methods of use thereof. Another embodiment may be directed to any of the disclosed pharmaceutical compositions, where the pharmaceutical composition is inhalable.

Abstract: Methods are disclosed to identify T lymphocyte genes that are differentially expressed upon exposure to a pathogen (viral or bacterial), immunogen, antigen, or in a sterile inflammatory disease, autoimmune disease, immunodeficiency disease, lymphocytic cancers, or graft versus host rejection. The method involves the preparation of a gene expression profile of a T lymphocyte population exposed to a pathogen or isolated from a subject having one of the aforementioned pathologies and comparing that profile to a profile prepared from quiescent T lymphocytes. The present invention is useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signalling molecules. Related methods for identifying therapeutic or prophylatic immunomodulatory agents are present.

Abstract: The present invention comprises a method to identify granulocytic cell genes that are differentially expressed upon exposure to a pathogen or in a sterile inflammatory disease by preparing a gene expression profile of a granulocytic cell population exposed to a pathogen or isolated from a subject having a sterile inflammatory disease and comparing that profile to a profile prepared from quiescent granulocytic cells. The present invention is particularly useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signaling molecules. The invention also includes methods to identify a therapeutic agent that modulates the expression of at least one gene in a granulocyte population. Genes which are differentially expressed during neutrophil contact with a pathogen, such as a virulent bacteria, or that are differentially expressed in a subject having a sterile inflammatory disease are of particular importance.

Abstract: The present invention comprises methods of identifying an agent that modulates sterile inflammatory disease by preparing a gene expression profile of a granulocytic cell population isolated from a subject having a sterile inflammatory disease; treating it with an agent; and comparing that profile to a profile prepared from untreated granulocytic cells isolated from a subject known to have sterile inflammatory disease. The invention also includes methods to identify such agents by treating an isolated polymorphonuclear white blood cell population from a patient with a sterile inflammatory disease with an agent and comparing it to a gene expression profile of an untreated polymorponuclear white blood cell population isolated from a patient with a sterile inflammatory disease. Agents that modulate glomerulonephritis are of particular importance.

Abstract: The present invention is directed to an approach to identify changes in gene expression by selective amplification of 3′ fragments of double stranded cDNAs.

Abstract: The present invention is directed to an approach to identify changes in gene expression by selective amplification of 3′ fragments of double stranded cDNAs.

Abstract: The present invention comprises a method to identify granulocytic cell genes that are differentially expressed upon exposure to a pathogen or in a sterile inflammatory disease by preparing a gene expression profile of a granulocytic cell population exposed to a pathogen or isolated from a subject having a sterile inflammatory disease and comparing that profile to a profile prepared from quiescent granulocytic cells. The present invention is particularly useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signaling molecules. The invention also includes methods to identify a therapeutic agent that modulates the expression of at least one gene in a granulocytic population. Genes which are differentially expressed during neutrophil contact with a pathogen, such as a virulent bacteria, or that are differentially expressed in a subject having a sterile inflammatory disease are of particular importance.

Abstract: The present invention is directed to an approach to study changes in gene expression by the selective PCR amplification and display of 3'-end restriction fragments of double stranded cDNAs.

Abstract: The present invention provides methods to analyze gene expression by selective PCR amplification and display of 3'-end restriction fragments of double stranded cDNAs.